BOSTON SCIENTIFIC CORP

Boston Scientific stock shows a bullish “hockey‑stick” rebound after a 2026 guidance cut—strong Q2 earnings, insider buying and a growing MiRus program hint at upside potential.

Boston Scientific’s 2026 restructuring plan cuts 2,500 jobs, slashes supply‑chain costs by 7 % and reallocates capital to digital‑health growth, aiming for $350 M annual savings.

Boston Scientific’s strategic acquisitions fuse diagnostics with cell‑therapy delivery, boosting safety, efficacy, and workflow efficiency in the evolving biologics market.

Boston Scientific’s revised target price shows a cautious outlook amid slowing growth, but its strategic acquisitions in a consolidating medical‑device market signal hidden upside and resilience.

Boston Scientific’s new 14 M incentive options boost capital while aligning staff, shareholders and patient outcomes, fueling R&D and value‑based reimbursement success.

Boston Scientific’s Watchman device faces slower growth, prompting a revised price target, but strong safety, efficacy and a diversified portfolio keep the “buy” rating intact.

Boston Scientific’s recent Form 4 filing shows CEO Mahoney’s ownership shift, yet the company’s solid cash flow, R&D focus on AI/digital health, and resilience to Medicare‑reimbursement changes keep it poised for growth in the competitive medical‑de…

Boston Scientific’s latest Form 4 filing reveals CEO Michael Mahoney’s direct share transfer to his trust—insider transparency, no operational impact.

Boston Scientific’s inclusion in SPY’s record‑high rally highlights its strong AI‑enabled medical devices, low safety risk, and robust regulatory strategy, boosting investor confidence and patient outcomes.

Boston Scientific’s FRACTURE trial proves its IVL catheter is safe and effective for calcified coronary lesions—boosting FDA prospects, investor confidence, and market potential.